Clinical
Pentixafor PET/CT program moves into U.S. phase 3
FDA clearance of the IND allows Pentixapharm to start the PANDA study of Ga-68 pentixafor for treatment-resistant hypertension with underlying primary aldosteronism.
Company
Pentixapharm
Company
FDA clearance of the IND allows Pentixapharm to start the PANDA study of Ga-68 pentixafor for treatment-resistant hypertension with underlying primary aldosteronism.